CD44 Expression and Tumour Cell Density Correlate with Response to Tamoxifen/carboplatin Chemotherapy in Glioblastomas

Overview

Journal J Neurooncol

Publisher Springer

Date 2004 Mar 16

PMID 15015779

Citations 2

Authors

Christian Hagel

Sung-Ho Park

Maximilian J A Puchner

Dimitrios Stavrou

Affiliations

Soon will be listed here.

Abstract

In order to identify response predictors for a post-operative glioblastoma therapy consisting of tamoxifen, carboplatin and radiotherapy, expression of 12 antigens was evaluated in 36 newly diagnosed tumours and 13 recurrences. Results were correlated with the clinical course of the disease. Antigen expression was assessed immunohistochemically for CD44s, TGF-beta2, TGF-alpha, progesterone receptor, estrogen receptor, EGFR, urokinase, urokinase inhibitor 1, CD87, p53 protein and Ki-67. Vessel density was determined by labelling of endothelia with von Willebrand factor. Response to chemotherapy correlated positively with cell density (p < 0.05) and negatively with CD44 over-expression (p < 0.02). Further, a positive correlation between age and CD44 expression (p < 0.05) and a negative correlation between age and p53 accumulation (p < 0.01) was found. In tumour recurrences expression of CD44 was significantly higher in local recurrences than in distant multifocal recurrences (p < 0.02), suggesting that CD44 may predominantly be associated with cell adhesion in glioblastomas.

Citing Articles

Whole-genome approach implicates CD44 in cellular resistance to carboplatin.

Shukla S, Duan S, Wu X, Badner J, Kasza K, Dolan M Hum Genomics. 2009; 3(2):128-42.

PMID: 19164090 PMC: 2683878. DOI: 10.1186/1479-7364-3-2-128.

Role of MIB1 in predicting survival in patients with glioblastomas.

Moskowitz S, Jin T, Prayson R J Neurooncol. 2005; 76(2):193-200.

PMID: 16234986 DOI: 10.1007/s11060-005-5262-1.

References

Rameshwar P, Chang V, Gascon P . Implication of CD44 in adhesion-mediated overproduction of TGF-beta and IL-1 in monocytes from patients with bone marrow fibrosis. Br J Haematol. 1996; 93(1):22-9. DOI: 10.1046/j.1365-2141.1996.4631004.x. View

Couldwell W, WEISS M, DeGiorgio C, Weiner L, Hinton D, Ehresmann G . Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery. 1993; 32(3):485-9; discussion 489-90. DOI: 10.1227/00006123-199303000-00034. View

Puchner M, Giese A . Tamoxifen-resistant glioma-cell sub-populations are characterized by increased migration and proliferation. Int J Cancer. 2000; 86(4):468-73. DOI: 10.1002/(sici)1097-0215(20000515)86:4<468::aid-ijc4>3.0.co;2-r. View

Puchner M, Herrmann H, Berger J, Cristante L . Surgery, tamoxifen, carboplatin, and radiotherapy in the treatment of newly diagnosed glioblastoma patients. J Neurooncol. 2001; 49(2):147-55. DOI: 10.1023/a:1026533016912. View

Khalid H, Shibata S, Kishikawa M, Yasunaga A, Iseki M, Hiura T . Immunohistochemical analysis of progesterone receptor and Ki-67 labeling index in astrocytic tumors. Cancer. 1997; 80(11):2133-40. DOI: 10.1002/(sici)1097-0142(19971201)80:11<2133::aid-cncr13>3.0.co;2-#. View

Ylagan L, Quinn B . CD44 expression in astrocytic tumors. Mod Pathol. 1998; 10(12):1239-46. View

Whittle I, Hawkins R, Miller J . Sex hormone receptors in intracranial tumours and normal brain. Eur J Surg Oncol. 1987; 13(4):303-7. View

Vaquero J, Zurita M, Morales C, Oya S, Coca S . Prognostic significance of endothelial surface score and MIB-1 labeling index in glioblastoma. J Neurooncol. 2000; 46(1):11-6. DOI: 10.1023/a:1006347919565. View

Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U . Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost. 1997; 78(1):285-96. View

10.

Scarpi E, de Paola F, Sarti M, Bajorko P, Granato A, Volpi A . Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2001; 68(2):101-10. DOI: 10.1023/a:1011975510181. View

11.

Hagel C, Schwartz P, Laas R, Stavrou D . Comparison of 4 proliferation markers and their significance for evaluation of tumor dignity in intracranial tumors. Int J Oncol. 2011; 7(1):107-13. DOI: 10.3892/ijo.7.1.107. View

12.

Nicholson R, McClelland R, Gee J, Manning D, Cannon P, Robertson J . Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat. 1994; 29(1):117-25. DOI: 10.1007/BF00666187. View

13.

Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H . Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996; 6(3):217-23; discussion 23-4. DOI: 10.1111/j.1750-3639.1996.tb00848.x. View

14.

Berns E, Klijn J, van Putten W, de Witte H, Look M, Meijer-van Gelder M . p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. J Clin Oncol. 1998; 16(1):121-7. DOI: 10.1200/JCO.1998.16.1.121. View

15.

Stavrou D, KEIDITSCH E, Schmidberger F, Bise K, Funke I, Eisenmenger W . Monoclonal antibodies against human astrocytomas and their reactivity pattern. J Neurol Sci. 1987; 80(2-3):205-20. DOI: 10.1016/0022-510x(87)90155-9. View

16.

Johansson M, Bergenheim A, Widmark A, Henriksson R . Effects of radiotherapy and estramustine on the microvasculature in malignant glioma. Br J Cancer. 1999; 80(1-2):142-8. PMC: 2362991. DOI: 10.1038/sj.bjc.6690333. View

17.

Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Muller K . Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol. 1997; 123(9):469-77. DOI: 10.1007/BF01192200. View

18.

Mastronardi L, Puzzilli F, Couldwell W, Farah J, Lunardi P . Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients. J Neurooncol. 1998; 38(1):59-68. DOI: 10.1023/a:1005968724240. View

19.

Kopp A, Jonat W, Schmahl M, Knabbe C . Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res. 1995; 55(20):4512-5. View

20.

Baltuch G, Couldwell W, Villemure J, Yong V . Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen. Neurosurgery. 1993; 33(3):495-501; discussion 501. DOI: 10.1227/00006123-199309000-00021. View